Type of Cancer
Genito-Urinary
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.